CN1674896A - 含有fk506衍生物的药物组合物及其用于治疗过敏性疾病的用途 - Google Patents

含有fk506衍生物的药物组合物及其用于治疗过敏性疾病的用途 Download PDF

Info

Publication number
CN1674896A
CN1674896A CNA038190176A CN03819017A CN1674896A CN 1674896 A CN1674896 A CN 1674896A CN A038190176 A CNA038190176 A CN A038190176A CN 03819017 A CN03819017 A CN 03819017A CN 1674896 A CN1674896 A CN 1674896A
Authority
CN
China
Prior art keywords
hydrogen atom
alkyl
macrocyclic lactone
lactone compounds
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038190176A
Other languages
English (en)
Chinese (zh)
Inventor
上野隆司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo Pharmaceuticals Inc
Original Assignee
Sucampo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Pharmaceuticals Inc filed Critical Sucampo Pharmaceuticals Inc
Publication of CN1674896A publication Critical patent/CN1674896A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
CNA038190176A 2002-08-09 2003-08-08 含有fk506衍生物的药物组合物及其用于治疗过敏性疾病的用途 Pending CN1674896A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40206102P 2002-08-09 2002-08-09
US60/402,061 2002-08-09

Publications (1)

Publication Number Publication Date
CN1674896A true CN1674896A (zh) 2005-09-28

Family

ID=31715781

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038190176A Pending CN1674896A (zh) 2002-08-09 2003-08-08 含有fk506衍生物的药物组合物及其用于治疗过敏性疾病的用途

Country Status (10)

Country Link
US (1) US20050239813A1 (enExample)
EP (1) EP1536793A1 (enExample)
JP (2) JP2005536531A (enExample)
KR (1) KR20050054913A (enExample)
CN (1) CN1674896A (enExample)
AU (1) AU2003256068A1 (enExample)
BR (1) BR0313425A (enExample)
CA (1) CA2495103A1 (enExample)
MX (1) MXPA05001575A (enExample)
WO (1) WO2004014373A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1965825B (zh) * 2005-11-17 2011-07-06 洪晶 一种治疗眼部免疫性疾病及抑制增殖、新生血管的眼表用药
CN106572995A (zh) * 2014-06-30 2017-04-19 尹特荣生物科技株式会社 含有fk506衍生物的用于治疗隐球菌属霉菌和念珠菌属霉菌引起的真菌感染的药剂学组合物及其用途

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033604B2 (en) * 2001-07-06 2006-04-25 Sucampo Ag Composition for topical administration
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20060258698A1 (en) 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
AU2006270041B2 (en) 2005-07-18 2011-08-18 Minu, Llc Enhanced ocular neuroprotection/neurostimulation
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
KR100891313B1 (ko) 2007-08-17 2009-03-31 (주) 제노텍 담체로 작용하는 흡착성 수지의 제공에 의한 트리사이클로화합물의 생산 및 추출 방법
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69016515T2 (de) * 1989-07-05 1995-06-08 Fujisawa Pharmaceutical Co Wässriges flüssiges Mittel zur äusserlichen Anwendung.
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
CA2102241C (en) * 1991-04-26 2003-12-30 Manabu Mochizuki Use of macrolide compounds for eye diseases
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
CZ20013769A3 (cs) * 1999-04-30 2002-03-13 Sucampo Ag Činidlo pro léčbu suchého oka
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
US7033604B2 (en) * 2001-07-06 2006-04-25 Sucampo Ag Composition for topical administration
EP1458405A1 (en) * 2001-11-21 2004-09-22 Sucampo AG Use of fk506 and analogues for treating allergic diseases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1965825B (zh) * 2005-11-17 2011-07-06 洪晶 一种治疗眼部免疫性疾病及抑制增殖、新生血管的眼表用药
CN106572995A (zh) * 2014-06-30 2017-04-19 尹特荣生物科技株式会社 含有fk506衍生物的用于治疗隐球菌属霉菌和念珠菌属霉菌引起的真菌感染的药剂学组合物及其用途

Also Published As

Publication number Publication date
BR0313425A (pt) 2005-07-05
EP1536793A1 (en) 2005-06-08
CA2495103A1 (en) 2004-02-19
MXPA05001575A (es) 2005-08-19
US20050239813A1 (en) 2005-10-27
JP2005536531A (ja) 2005-12-02
WO2004014373A1 (en) 2004-02-19
KR20050054913A (ko) 2005-06-10
AU2003256068A1 (en) 2004-02-25
JP2011012071A (ja) 2011-01-20

Similar Documents

Publication Publication Date Title
CN1259049C (zh) 包含白介素－2抑制剂和抗菌剂的局部给药组合物
CN1190194C (zh) 用于治疗干眼的大环内酯化合物的应用
JP2011012071A (ja) アレルギー性疾患を処置する為のｆｋ５０６誘導体を含む医薬組成物及びその使用
US7063857B1 (en) Use of macrolide compounds for the treatment of dry eye
US6864232B1 (en) Agent for treating visual cell function disorder
JP2004529928A (ja) 眼炎症疾患用眼局所処置剤
US20040198763A1 (en) Method of treating dry eye with a macrolide compound
CN1224420C (zh) 视细胞功能紊乱治疗剂
CN1133429C (zh) 大环内酯化合物用于治疗成人呼吸窘迫综合症的用途
US20050070468A1 (en) Use of fk506 and analogues for treating allergic diseases
KR20050071491A (ko) 천식의 치료를 위한 베타2-작용제와 배합된 타크롤리무스 (ｆｋ506) 유도체의 용도
KR20040002980A (ko) 트리사이클릭 화합물을 포함하는 피부 질환의 예방 또는치료용 약제학적 조성물
HK1036406B (en) Use of macrolide compounds for the treatment of ards
AU2002248014A1 (en) Agent for topical ophthalmic treatment of ocular inflammatory diseases
HK1070282A (en) Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication